Monte Rosa Therapeutics, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
GLUE Nasdaq 2836 www.monterosatx.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Monte Rosa Therapeutics, Inc.

Monte Rosa Therapeutics (GLUE): Best Growth Stocks Under $20 to Buy - Jun 3rd, 2026 12:00 pm
Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Jun 2nd, 2026 2:01 pm
Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences - May 20th, 2026 5:00 am
Monte Rosa Trial Progress And Valuation Gap Draw Investor Attention - May 9th, 2026 6:24 pm
Monte Rosa Therapeutics (GLUE) Reports Q1 Loss, Misses Revenue Estimates - May 7th, 2026 9:15 am
Monte Rosa Therapeutics Announces First Quarter 2026 Financial Results and Business Updates - May 7th, 2026 5:00 am
Myriad Genetics (MYGN) Reports Q1 Loss, Misses Revenue Estimates - May 5th, 2026 6:30 pm
Monte Rosa CEO Sells $141K in Stock Amid 300% Surge and Recent Capital Raise - Apr 21st, 2026 11:53 am
Monte Rosa Therapeutics Presents Preclinical Data at American Association for Cancer Research (AACR) Annual Meeting 2026 on the Potential of its Cyclin E1 (CCNE1)-directed Molecular Glue Degrader to Treat CCNE1-amplified Solid Tumors - Apr 20th, 2026 5:00 am
Monte Rosa J J Supply Deal Refocuses MRT 2359 Prostate Cancer Story - Mar 21st, 2026 5:07 am
Exchange-Traded Funds Higher, Equity Futures Mixed Pre-Bell Tuesday Ahead of US Federal Reserve Meeting - Mar 17th, 2026 6:56 am
Monte Rosa Therapeutics touts molecular glue pipeline, tees up GFORCE updates and Phase II plans - Mar 17th, 2026 6:40 am
Monte Rosa Therapeutics (GLUE) Reports Q4 Loss, Misses Revenue Estimates - Mar 17th, 2026 6:25 am
Monte Rosa Therapeutics: Q4 Earnings Snapshot - Mar 17th, 2026 5:33 am
Monte Rosa Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Business Updates - Mar 17th, 2026 5:00 am
Agenus (AGEN) Q4 Earnings and Revenues Surpass Estimates - Mar 16th, 2026 6:35 pm
Monte Rosa Therapeutics Announces Clinical Supply Agreement to Support Phase 2 Trial Evaluating MRT-2359 in Combination with Apalutamide for the Treatment of Metastatic Castration-Resistant Prostate Cancer - Mar 16th, 2026 5:00 am
Monte Rosa Therapeutics (GLUE) Expected to Beat Earnings Estimates: Can the Stock Move Higher? - Mar 12th, 2026 8:00 am
Assessing Monte Rosa Therapeutics (GLUE) Valuation After MRT-2359 Data Update And New Public Offering - Mar 7th, 2026 10:09 pm
How Monte Rosa’s MRT-2359 Prostate Cancer Data and Funding Plans Could Shape GLUE’s Risk‑Reward Profile - Mar 7th, 2026 7:06 pm